Background: Percutaneous device closure was shown to effectively prevent recurrent strokes in patients with patent foramen ovale (PFO). Whether this protective effect is relevant for patients with hypercoagulable states (HCSs) is unknown as they were not represented in prior studies. Methods: Data on 136 consecutive patients with a PFO and clinically significant HCS were retrospectively collected. PFO closure and antithrombotic regimen were decided on an individual basis by the treating physicians, and adherence to therapy was routinely evaluated. The outcome was the occurrence of cerebrovascular accident (CVA) or transient ischemic attack (TIA). Results: HCS types consisted of antiphospholipid syndrome (31%), factor-5 Leiden mutation (22%), prothrombin mutation (18%), protein S deficiency (15%), protein C deficiency (7%), methyl-tetra-hydro folate reductase mutation (5%), and essential thrombocytosis (2%). 102 patients (75%) were maintained on anticoagulants and the remaining on antiplatelet therapy. PFO closure was undertaken in 85 (63%); antithrombotic therapy was not interrupted prior to or after the procedures. At a mean follow-up of 46 ± 8 months, 23 patients (17%; 95% confidence interval, 9.3–22%) experienced an outcome event, mainly in the form of CVAs (n = 15, 65%). In multivariable analysis, PFO closure was associated with a 5-fold decrease in the risk of CVA/TIA (p = 0.02). This effect was independent of the type of HCS or antithrombotic therapy. Conclusions: Among patients with HCSs maintained on anticoagulant or antiplatelet therapies, PFO closure was associated with a significantly lower risk of CVA or TIA.

1.
Hagen
PT
,
Scholz
DG
,
Edwards
WD
.
Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts
.
Mayo Clin Proc
.
1984
;
59
(
1
):
17
20
. .
2.
Lechat
P
,
Mas
JL
,
Lascault
G
,
Loron
P
,
Theard
M
,
Klimczac
M
, et al
Prevalence of patent foramen ovale in patients with stroke
.
N Engl J Med
.
1988
;
318
(
18
):
1148
52
. .
3.
Alsheikh-Ali
AA
,
Thaler
DE
,
Kent
DM
.
Patent foramen ovale in cryptogenic stroke: incidental or pathogenic?
Stroke
.
2009
;
40
(
7
):
2349
55
. .
4.
Khairy
P
,
O’Donnell
CP
,
Landzberg
MJ
.
Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review
.
Ann Intern Med
.
2003 Nov 4
;
139
(
9
):
753
60
. .
5.
Furlan
AJ
,
Reisman
M
,
Massaro
J
,
Mauri
L
,
Adams
H
,
Albers
GW
, et al
Closure or medical therapy for cryptogenic stroke with patent foramen ovale
.
N Engl J Med
.
2012
;
366
:
991
9
. .
6.
Meier
B
,
Kalesan
B
,
Mattle
HP
,
Khattab
AA
,
Hildick-Smith
D
,
Dudek
D
, et al
Percutaneous closure of patent foramen ovale in cryptogenic embolism
.
N Engl J Med
.
2013
;
368
(
12
):
1083
91
. .
7.
Søndergaard
L
,
Kasner
SE
,
Rhodes
JF
,
Andersen
G
,
Iversen
HK
,
Nielsen-Kudsk
JE
, et al
Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke
.
N Engl J Med
.
2017
;
377
(
11
):
1033
42
. .
8.
Mas
JL
,
Derumeaux
G
,
Guillon
B
,
Massardier
E
,
Hosseini
H
,
Mechtouff
L
, et al
Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke
.
N Engl J Med
.
2017
;
377
(
11
):
1011
21
. .
9.
Saver
JL
,
Carroll
JD
,
Thaler
DE
,
Smalling
RW
,
MacDonald
LA
,
Marks
DS
, et al
Long-term outcomes of patent foramen ovale closure or medical therapy after stroke
.
N Engl J Med
.
2017
;
377
(
11
):
1022
32
. .
10.
Pristipino
C
,
Sievert
H
,
D’Ascenzo
F
,
Louis Mas
J
,
Meier
B
,
Scacciatella
P
, et al
European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism
.
Eur Heart J
.
2019
;
40
(
38
):
3182
95
. .
11.
Kerut
EK
,
Norfleet
WT
,
Plotnick
GD
,
Giles
TD
.
Patent foramen ovale: a review of associated conditions and the impact of physiological size
.
J Am Coll Cardiol
.
2001
;
38
(
3
):
613
23
. .
12.
Silvestry
FE
,
Kerber
RE
,
Brook
MM
,
Carroll
JD
,
Eberman
KM
,
Goldstein
SA
, et al
Echocardiography-guided interventions
.
J Am Soc Echocardiogr
.
2009
;
22
(
3
):
213
7
.
[Erratum, J Am Soc Echocardiogr. 2009;22:336]
. .
13.
Cervera
R
,
Serrano
R
,
Pons-Estel
GJ
,
Ceberio-Hualde
L
,
Shoenfeld
Y
,
de Ramón
E
, et al
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1,000 patients
.
Ann Rheum Dis
.
2015
;
74
(
6
):
1011
8
. .
14.
Lichy
C
,
Reuner
KH
,
Buggle
F
,
Litfin
F
,
Rickmann
H
,
Kunze
A
, et al
Prothrombin G20210A mutation, but not factor V Leiden, is a risk factor in patients with persistent foramen ovale and otherwise unexplained cerebral ischemia
.
Cerebrovasc Dis
.
2003
;
16
(
1
):
83
7
. .
15.
Franchini
M
,
Veneri
D
,
Salvagno
GL
,
Manzato
F
,
Lippi
G
.
Inherited thrombophilia
.
Crit Rev Clin Lab Sci
.
2006
;
43
(
3
):
249
90
. .
16.
Pezzini
A
,
Del Zotto
E
,
Magoni
M
,
Costa
A
,
Archetti
S
,
Grassi
M
, et al
Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale
.
Stroke
.
2003
;
34
(
1
):
28
33
. .
17.
Botto
N
,
Spadoni
I
,
Giusti
S
,
Ait-Ali
L
,
Sicari
R
,
Andreassi
MG
.
Prothrombotic mutations as risk factors for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale
.
Stroke
.
2007
;
38
(
7
):
2070
3
. .
18.
Favaretto
E
,
Sartori
M
,
Conti
E
,
Legnani
C
,
Palareti
G
.
G1691A factor V and G20210A FII mutations, acute ischemic stroke of unknown cause, and patent foramen ovale
.
Thromb Res
.
2012
;
130
(
5
):
720
4
. .
19.
Douketis
JD
,
Spyropoulos
AC
,
Spencer
FA
,
Mayr
M
,
Jaffer
AK
,
Eckman
MH
, et al
Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines
.
Chest
.
2012
;
141
:
e326S
50S
.
20.
Garcia
DA
,
Regan
S
,
Henault
LE
,
Upadhyay
A
,
Baker
J
,
Othman
M
, et al
Risk of thromboembolism with short-term interruption of warfarin therapy
.
Arch Intern Med
.
2008
;
168
(
1
):
63
9
. .
21.
Douketis
JD
,
Spyropoulos
AC
,
Kaatz
S
,
Becker
RC
,
Capirini
JA
,
Dunn
AS
, et al
Review of article: perioperative bridging anticoagulation in patients with atrial fibrillation by James D. Douketis, MD, Alex C. Spyropoulos, MD, Scott Kaatz, DO, et al (N Engl J Med 2015;373: 823–833)
.
J Vasc Nurs
.
2015
;
33
(
4
):
167
8
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.